Publications by authors named "Philip D Home"

Claim this Profile
A
An overview of insulin therapy for the non-specialist.
Philip D Home

Diabetes Obes Metab· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Modern Role of Basal Insulin in Advancing Therapy in People With Type 2 Diabetes.
Geremia B Bolli, Philip D Home, Francesca Porcellati, Matthew C Riddle, Hertzel C Gerstein

Diabetes Care· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Findings for iGlarLixi versus BIAsp 30 confirmed in groups of people with type 2 diabetes with different biomedical characteristics.
Philip D Home, Rory J McCrimmon, Julio Rosenstock, Matthias Blüher, Katrin Pegelow

Diabetes Obes Metab· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of iGlarLixi versus IDegAsp: Results of a systematic literature review and indirect treatment comparison.
Philip D Home, Roopa Mehta, Khadija A S Hafidh, Olesya Y Gurova, Agustina Alvarez

Diabetes Obes Metab· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Insulin therapy development beyond 100 years.
Philip D Home, Roopa Mehta

Lancet Diabetes Endocrinol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lingering Effects of Hyperglycemia in Recently Diagnosed Diabetes During Long-term Follow-up of the DCCT/EDIC and UKPDS Cohorts: More Evidence That Early Control Matters.
Matthew C Riddle, Hertzel C Gerstein, Philip D Home

Diabetes Care· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists: a systematic literature review and indirect treatment comparison.
Philip D Home, Vanita R Aroda, Lawrence Blonde, Patricia Guyot, Alka Shaunik

Diabetes Obes Metab· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypoglycaemia risk with insulin glargine 300 U/mL compared with glargine 100 U/mL across different baseline fasting C-peptide levels in insulin-naïve people with type 2 diabetes: A post hoc analysis of the EDITION 3 trial.
Geremia B Bolli, Wolfgang Landgraf, Zsolt Bosnyak, Lydie Melas-Melt, Philip D Home

Diabetes Obes Metab· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of Multiple Cut Points for Time in Range in Relation to Risk of Abnormal Carotid Intima-Media Thickness and Diabetic Retinopathy.
Jingyi Lu, Philip D Home, Jian Zhou

Diabetes Care· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Commencing insulin glargine 100 U/mL therapy in individuals with type 2 diabetes: Determinants of achievement of HbA1c goal less than 7.0.
David R Owens, Wolfgang Landgraf, Brian M Frier, Mei Zhang, Philip D Home

Diabetes Obes Metab· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes: A randomized, open-label clinical trial.
Priscilla A Hollander, Wendy L Carofano, Raymond L H Lam, Gregory T Golm, Roy Eldor, Philip D Home

Diabetes Obes Metab· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: A randomized, open-label clinical trial.
Philip D Home, Raymond L H Lam, Wendy L Carofano, Gregory T Golm, Roy Eldor

Diabetes Obes Metab· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (EDITION 4).
Philip D Home, Richard M Bergenstal, Geremia B Bolli, Monika Ziemen, Maria Rojeski

Diabetes Obes Metab· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy.
Philip D Home, Bo Ahrén, Jane E B Reusch, Marc Rendell, Peter N Weissman

Diabetes Res Clin Pract· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comment on Pathak et al. Severe Hypoglycemia Requiring Medical Intervention in a Large Cohort of Adults With Diabetes Receiving Care in U.S. Integrated Health Care Delivery Systems: 2005-2011. Diabetes Care 2016:39;363-370.
Philip D Home

Diabetes Care· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glucose Control and Vascular Outcomes in Type 2 Diabetes: Is the Picture Clear?
Francesco Giorgino, Philip D Home, Jaakko Tuomilehto

Diabetes Care· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U/mL in People with Type 2 Diabetes.
Matthew C Riddle, Geremia B Bolli, Philip D Home, Richard M Bergenstal, Monika Ziemen

Diabetes Technol Ther· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4).
Philip D Home, Richard M Bergenstal, Geremia B Bolli, Monika Ziemen, Maria Rojeski

Diabetes Care· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From a Diabetes Care Editors' Expert Forum.
William T Cefalu, George A Bray, Philip D Home, W Timothy Garvey, Samuel Klein

Diabetes Care· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer and bone fractures in observational follow-up of the RECORD study.
Nigel P Jones, Paula S Curtis, Philip D Home

Acta Diabetol· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of HbA1c over 4 years in people with type 2 diabetes starting insulin therapies: The CREDIT study.
Beverley Balkau, Françoise Calvi-Gries, Nick Freemantle, Maya Vincent, Valerie Pilorget, Philip D Home

Diabetes Res Clin Pract· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Four-year evolution of insulin regimens, glycaemic control, hypoglycaemia and body weight after starting insulin therapy in type 2 diabetes across three continents.
Philip D Home, Marie-Paule Dain, Nick Freemantle, Ryuzo Kawamori, Martin Pfohl

Diabetes Res Clin Pract· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to comment on Balkau et al. Factors associated with weight gain in people with type 2 diabetes starting on insulin. Diabetes Care 2014;37:2108-2113.
Beverley Balkau, Philip D Home, Maya Vincent, Michel Marre, Nick Freemantle

Diabetes Care· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1).
Matthew C Riddle, Geremia B Bolli, Monika Ziemen, Isabel Muehlen-Bartmer, Florence Bizet, Philip D Home

Diabetes Care· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forum.
William T Cefalu, John B Buse, Stefano Del Prato, Philip D Home, Derek LeRoith

Diabetes Care· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis